Revance Therapeutics (RVNC) Short Interest Ratio & Short Volume

Short interest is the volume of Revance Therapeutics shares that have been sold short but have not yet been covered or closed out. As of December 31st, investors have sold 8,340,000 shares of RVNC short. Learn More on Revance Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RVNC shares currently have a short interest ratio of 3.0. Learn More on Revance Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Revance Therapeutics: Jane Street Group LLC, Polar Asset Management Partners Inc., Centiva Capital LP, Bardin Hill Management Partners LP, Glazer Capital LLC, Wolverine Asset Management LLC, and Cannon Global Investment Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Revance Therapeutics saw a drop in short interest during the month of December. As of December 31st, there was short interest totaling 8,340,000 shares, a drop of 14.6% from the previous total of 9,770,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Revance Therapeutics: Ardelyx, Inc. (10.25%), Nurix Therapeutics, Inc. (15.23%), Kiniksa Pharmaceuticals, Ltd. (4.70%), Arcus Biosciences, Inc. (15.73%), Maravai LifeSciences Holdings, Inc. (3.37%), Ocular Therapeutix, Inc. (6.83%), Arvinas, Inc. (13.80%), Calliditas Therapeutics AB (publ) (0.01%), Day One Biopharmaceuticals, Inc. (25.54%), Praxis Precision Medicines, Inc. (10.98%),

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks.

Short selling RVNC is an investing strategy that aims to generate trading profit from Revance Therapeutics as its price is falling. RVNC shares are trading up $0.41 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Revance Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RVNC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RVNC, twice per month. The most recent reporting period available is December, 31 2024.